SCHEMBL2324462

SCHEMBL2324462

ICC1(CI)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15908763 0.84
SCHEMBL30753323 0.84
SCHEMBL19509973 0.80
SCHEMBL12511174 0.78
SCHEMBL21315206 0.76
SCHEMBL21975274 0.69
SCHEMBL20646581 0.67
SCHEMBL21976161 0.66
SCHEMBL21316207 0.66
SCHEMBL15355223 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492194-B2 HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-09 US disclosed
EP-4655298-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Theras Inc. (US) 2025-12-03 EP disclosed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 US disclosed
EP-3947366-B1 HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 EP disclosed
US-20250154153-A1 DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) 2025-05-15 US disclosed
WO-2025054431-A1 BENZO-FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF XENON PHARMACEUTICALS INC. (CA) 2025-03-13 WO disclosed
WO-2024158778-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS THERAS, INC. (US) 2024-08-02 WO disclosed
US-20240182465-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2024-06-06 US disclosed
EP-4303216-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2024-01-10 EP disclosed
US-20230339947-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS Madera Therapeutics, LLC 2023-10-26 US disclosed
CN-102203077-B (pyrrolidin-2-yl) phenyl derivatives for the treatment of pain MERCK SHARP & DOHME 2014-07-09 CN disclosed
WO-2014028669-A1 NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY BIOGEN IDEC MA INC. (US) 2014-02-20 WO disclosed
EP-2356105-B1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN MSD OSS BV (NL) 2013-04-10 EP disclosed
US-8227480-B2 Indazole derivative having spiro ring structure in side chain UBE INDUSTRIES, LTD. (JP) 2012-07-24 US disclosed
US-8188123-B2 (Pyrrolidin-2-yl)phenyl derivatives MERCK SHARP & DOHME B.V. (NL) 2012-05-29 US disclosed
EP-2356105-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. Organon (NL) 2011-08-17 EP disclosed
WO-2010052198-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. ORGANON (NL) 2010-05-14 WO disclosed
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES N.V. ORGANON 2010-05-06 US disclosed
US-20090170887-A1 Novel indazole derivative having spiro ring structure in side chain SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-07-02 US disclosed
EP-2025676-A1 NOVEL INDAZOLE DERIVATIVE HAVING SPIRO RING STRUCTURE IN SIDE CHAIN Ube Industries, Ltd. (JP) 2009-02-18 EP disclosed